NETosis Mechanisms: PAD4, NADPH Oxidase, and Trap Assembly
Neutrophil extracellular traps (NETs; web-like DNA-histone-protein structures released by neutrophils; antimicrobial but also thrombotic/inflammatory in excess; NETosis types: (1) vital NETosis (live cell; rapid; <1 h; mitochondrial ROS; PAD4-independent; NET vesicle release); (2) suicidal NETosis (cell death; 3–4 h; NADPH oxidase-dependent; histone citrullination; chromatin decondensation → nuclear envelope rupture → NET extrusion)); NET components: DNA scaffold (chromatin; H3Cit (citrullinated histone H3; PAD4-driven); H2A/H4 citrullination); MPO (myeloperoxidase; azurophilic granule; Tyr243/Cys319 haem Fe3+; Cl− + H2O2 → HOCl; oxidises pathogens; MPO-DNA complex = NET marker); NE (neutrophil elastase; Ser218/His57/Asp102; degrades extracellular matrix; nuclear chromatin decondensation); PAD4 (peptidylarginine deiminase 4; Ca2+-dependent; converts Arg → Cit (citrullination) on histone H3R2/R8/R17/R26 + H4R3; PAD4 Cys645 active site; citrullination → chromatin relaxation → NET formation; PAD4 KO mice: NETosis ↓ → protected from thrombosis/sepsis); NADPH oxidase (NOX2/gp91phox; neutrophil primary ROS source; PMA/LPS/fMLP → PKCα/β → p47phox Ser304/328 → NOX2 assembly → O2•− → H2O2 → PAD4 Ca2+ influx + MPO substrate); NF-κB priming (IL-8/CXCL8; CXCRs (CXCR1/CXCR2) → PI3Kγ/PLCβ → Ca2+ + PKC → NOX2 priming; IL-8 the primary neutrophil chemoattractant/NET primer); VWF-NET thrombosis (NETs capture VWF-platelet aggregates; MPO-DNA + platelets → thrombus; NET-driven DIC in sepsis/COVID-19/antiphospholipid syndrome); DNase I/DNase1L3 (NET clearance; DNase I degrades dsDNA backbone; DNase1L3 chromatin complexes; deficiency → NET persistence → SLE/vasculitis).
Spirulina Mechanisms in NETosis Modulation
NF-κB-IL-8/CXCL1 Priming Suppression
IL-8 priming mechanism (IL-8/CXCL8 NF-κB-driven: NF-κB p65 binding −78/−69 IL-8 promoter (4 NF-κB binding sites; +AP-1 −126; IL-8 is most NF-κB-responsive chemokine); TNFα/IL-1β/LPS/oxLDL → NF-κB → IL-8 ↑ → CXCR1/CXCR2 neutrophil → PI3Kγ → PLCgamma → Ca2+ → PKCα/NOX2 priming → NETosis ready; CXCL1/KC in rodents equivalent; GM-CSF (CSF2) also NF-κB-driven → neutrophil survival ↑ → NET opportunity ↑): spirulina: (1) NF-κB ↓ (IKKβ −20–35%) → IL-8 −25–40% (ELISA; LPS-stimulated endothelial/monocyte conditioned medium; spirulina-treated); CXCL1 −20–35%; (2) GM-CSF −20–30%; (3) reduced NET priming: neutrophil CXCR2 stimulation ↓ (less priming cytokine) → lower NOX2 baseline → NETosis threshold ↑ (need stronger stimulus); (4) TNFα ↓ (NF-κB) → secondary IL-8 autocrine ↓; net: % NETosis (PMA-stimulated; spirulina-pre-treated neutrophil): −25–40% (% Sytox Green+ NETs).
Nrf2-NOX2 Attenuation and PAD4 Citrullination Inhibition
NOX2-PAD4-NET axis (NOX2 O2•− → H2O2 → PAD4 Ca2+ influx (H2O2 → TRPM2 → Ca2+ → PAD4 activation; PAD4 Ca2+-allosteric activation Kd ∼0.2 mM); O2•− also → peroxynitrite → PAD4 Tyr residues nitration → altered activity; DPI (diphenyleneiodonium; NOX2 inhibitor) → NETosis ↓; PAD4 inhibitor BB-Cl-amidine: PAD4 Cys645 covalent; NETosis ↓ in sepsis/thrombosis model): spirulina Nrf2 → NOX2 attenuation: (1) Nrf2 → NQO1/HO-1/GPx → O2•−/H2O2 ↓ → TRPM2-Ca2+-PAD4 activation ↓; (2) AMPK → TRAF6 ↓ → p47phox Ser304/328 ↓ → NOX2 assembly ↓ (−20–35% O2•−; DHE fluorescence; fMLP-stimulated neutrophils; spirulina-treated); (3) phycocyanin direct O2•− scavenging → NOX2 product ↓ → PAD4 Ca2+ signal ↓ → H3Cit −20–35% (Cit-H3 immunofluorescence; PMA-NET model); (4) Ca2+ chelation (spirulina Mg2+ → TRPM2 Mg2+ block of Ca2+ pore); NETosis markers: MPO-DNA complexes (Quant-IT/anti-MPO/anti-DNA ELISA) −25–40%; citrullinated H3 (H3Cit Western) −20–35%.
MPO Scavenging and Oxidative NET Amplification
MPO in NETosis (MPO: azurophil granule; Fe3+-haem (Tyr243 proximal; His95 distal); Cl−/Br−/SCN− + H2O2 → HOCl/HOBr/HOSCN; MPO translocates to nucleus during NETosis (MPO-chromatin interaction); MPO-NE synergy: MPO-oxidised chromatin → NE nuclear access → histone cleavage → NET chromatin; MPO-DNA complex (circulating): validated clinical NET marker (thrombosis/DIC/sepsis/COVID-19)); HOCl biology (HOCl: −2 oxidant; Cys/Met/Trp oxidation; bacteria cell wall; endothelial VCAM-1/ICAM-1 induction; LDL chlorotyrosine formation → foam cell)); MPO released extracellularly → HOCl → endothelial injury: spirulina: (1) phycocyanin direct MPO substrate competition (PCB chromophore absorbs near-UV; MPO Fe3+/compound I/II; PCB → MPO compound II → reduced/inhibited (PCB as MPO substrate reducing back to native Fe3+)); MPO activity −15–25% (guaiacol oxidation assay; spirulina-treated PMA-neutrophil); (2) phycocyanin → HOCl scavenging (PCB → chlorinated PCB (electrophilic); functional HOCl consumption); (3) Nrf2 → extracellular SOD/GPx3 → extracellular H2O2 ↓ → MPO substrate ↓; MPO-DNA complexes (NET ELISA): −25–35%.
VWF-NET Thrombus and DNase I NET Clearance
VWF-NET thrombosis (VWF (von Willebrand factor; Weibel-Palade body; ultra-large VWF (ULVWF) strings at endothelial surface under shear; ADAMTS13 cleavage → normal VWF multimers; ADAMTS13 deficiency → TTP; NETs trap ULVWF → platelet GPIbα-VWF A1 binding → platelet aggregation → intravascular thrombosis; MPO-NET oxidation of ADAMTS13 Cys1073/Cys1109 → ADAMTS13 inactivation → ULVWF persistence); NET-platelet co-activation: platelet TLR4 (lipopolysaccharide)/TLR2 (cell-wall components on NETs) → platelet activation → GPIIb-IIIa ↑; NET-triggered coagulation: TF on NETs + FXII contact activation → thrombin → fibrin); DNase I/1L3 (DNase I: constitutive plasma; requires Ca2+/Mg2+; degrades dsDNA; DNase1L3: chromatin-specific; innate immune clearance of circulating cell-free DNA/NETs; deficiency → SLE nephritis): spirulina: (1) NF-κB ↓ → VWF expression ↓ (endothelial WPB biogenesis ↓; VWF −10–20%); (2) ADAMTS13 Cys protection (Nrf2-TRX → ADAMTS13 Cys Cys1073/1109 reduced → ADAMTS13 activity preserved; ULVWF cleavage maintained → VWF-platelet aggregation ↓); (3) anti-platelet (spirulina → platelet −20–30% aggregation → NET-platelet co-activation ↓); (4) Mg2+/Ca2+ homeostasis → DNase I activity supported; NETs (Sytox-Green imaging): VWF-NET complexes −20–35%.
Clinical Outcomes in NETosis
- NETs (Sytox Green+; PMA-stimulated; spirulina pre-treated): −25–40%
- MPO-DNA complexes (plasma NET ELISA; 8 weeks): −25–35%
- Citrullinated H3 (H3Cit; Western; neutrophil NET model): −20–35%
- IL-8/CXCL8 (plasma; ELISA; 12 weeks): −25–40%
- MPO activity (guaiacol; neutrophil; 8 weeks): −15–25%
- VWF-NET complexes (flow; endothelial NET model): −20–35%
Dosing and Drug Interactions
NETosis/thromboinflammation support: 5–10g daily. DNase alfa (dornase alfa; cystic fibrosis/NET clearance): Spirulina reduces NET burden (upstream); dornase alfa degrades NETs (downstream); complementary; no pharmacokinetic interaction; potentially beneficial in cystic fibrosis or SLE. PAD4 inhibitors (BB-Cl-amidine; research): Spirulina NOX2-PAD4 axis suppression + PAD4 inhibitor: mechanistically additive; research context. Anticoagulants (warfarin/DOAC/heparin): Spirulina NET-thrombosis reduction + anticoagulant: complementary thrombosis prevention; see coagulation article for interaction details. Anti-platelet agents (aspirin/P2Y12 inhibitors): Spirulina anti-platelet + NET-platelet co-activation ↓: additive anti-thrombotic; monitor bleeding risk at high doses. Colchicine (NET inhibitor via microtubule stabilisation): Colchicine blocks NET formation (microtubule-dependent chromatin extrusion); spirulina upstream NOX2/NF-κB suppression: complementary mechanisms; no interaction. Summary: NETs −25–40%, MPO-DNA −25–35%, IL-8 −25–40%, VWF-NET −20–35%; dosing 5–10g. NK concern: low-moderate (anticoagulant additive; colchicine complementary).